Skip to content

Study · Systematic review · n = 646 · 2026

2 results

Divergent effect of diabetes on fibrosis response to semaglutide and resmetirom in noncirrhotic MASH: A meta-analysis of randomized trials.

Musso G, Pinach S, Cassader M, Mariano F, Gambino R

Med (New York, N.Y.)28 Jan 2026

PMID41610839 (opens in a new tab)DOI10.1016/j.medj.2025.100959 (opens in a new tab)PepBankPUB-41610839
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with noncirrhotic MASH and type 2 diabetes, semaglutide did not significantly improve fibrosis stage versus placebo (RR 1.21).

    In plain wordsIn adults with fatty liver disease (MASH) and type 2 diabetes, semaglutide did not improve liver scarring more than placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeFibrosis improvement of at least 1 stage in MASH with T2DM
    Study

    n = 646

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 52-72 weeksAs given in this study (human).

    Measurements

    RR
    1.21 ratio
    semaglutide, MASH with T2DM
    95% CI
    0.94 to 1.56 ratio
    semaglutide, MASH with T2DM

    Source sentences

    Summary
    semaglutide did not improve fibrosis stage (RR = 1.21, 95% CI 0.94-1.56, p = 0.13; I2 = 0%, N comparisons = 4, 646 participants
    1 context sentence
    Summary · context
    Eight out of 3,751 identified records, describing three placebo-controlled RCTs with histological endpoints (2,086 noncirrhotic MASH patients, 62% with T2DM, trial duration range 52-72 weeks) were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with noncirrhotic MASH without type 2 diabetes, semaglutide improved fibrosis stage versus placebo (RR 1.72).

    In plain wordsIn adults with fatty liver disease (MASH) without type 2 diabetes, semaglutide improved liver scarring more than placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseFibrosis improvement of at least 1 stage in MASH without T2DM
    Study

    n = 474

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 52-72 weeksAs given in this study (human).

    Measurements

    RR
    1.72 ratio
    semaglutide, MASH without T2DM
    95% CI
    1.21 to 2.44 ratio
    semaglutide, MASH without T2DM

    Source sentences

    Summary
    semaglutide improved fibrosis stage (RR = 1.72, 95% CI 1.21-2.44, p = 0.002, N comparisons = 4, I2 = 3%, 474 participants
    1 context sentence
    Summary · context
    Eight out of 3,751 identified records, describing three placebo-controlled RCTs with histological endpoints (2,086 noncirrhotic MASH patients, 62% with T2DM, trial duration range 52-72 weeks) were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.